Table 3. A summary of cardiovascular outcomes in SGLT-2i vs Placebo.

RCT=Randomized Controlled Trials, CI=Confidence Interval, MACE=Major Adverse Cardiovascular Events, CV=Cardiovascular, MI=Myocardial Infarction, HF=Heart Failure

 

RCT vs Placebo	Population studied	Intervention	Median follow up	Primary Outcome measured	Hazard Ratio for Primary Outcome	95% Confidence Interval (CI) and P value
EMPA-REG 2016 [14]	7020	Empagliflozin 10mg, 20mg vs Placebo	3.1 years	Composite of Cardiovascular death	0.61	95% CI 0.55-0.69   P value <0.001
CANVAS 2017 [10]	9734	Canagliflozin 100mg, 300mg vs Placebo	2.43 years	MACE	0.86	95% CI 0.75-0.97   P value <0.001
DECLARE TIMI-58 2018 [7]	17160	Dapagliflozin 10mg vs Placebo	4.2 years	Composite of CV death or HF hospitalization	0.83 (lower HF hospitalizations)	95% CI 0.73-0.95   P value = 0.005
CREDENCE 2019 [15]	4401	Canagliflozin 100mg vs Placebo	2.62 years	Composite of end-stage kidney disease or death from renal or CV causes	0.7	95% CI 0.59-0.82     P value = 0.00001
DAPA-HF 2020 [18]	4742	Dapagliflozin 5mg, 10mg vs Placebo	1.5 years	Composite of worsening HF or CV death	0.75	95% CI 0.63-0.9    P value 0.002
EMPEROR-REDUCED 2020 [20]	3730	Empagliflozin 10mg vs Placebo	1.3 years	Composite of CV death or HF hospitalization	0.75	95% CI 0.65 to 0.86  P value <0.001
VERTIS-CV 2020 [21]	8238	Ertugliflozin 5mg, 15mg vs Placebo	3.5 years	MACE	0.97	95% CI 0.85-1.11  P value <0.001